clients I've worked with

1617398168-ecplogo-large-4

Presenters

Who will be speaking

Event detail

All events

We organize for you

Home

Knowledge Bank

Industry Coverage

ECP Team

Technology

Mailing list signup

WSGR.com

Privacy Policy

Terms of Use

Generators

Aviation

Biotech

Blockchain and Cryptocurrency

Clean Energy

Climate and Clean Technologies

Communications and Networking

Consumer Products and Services

Data Storage and Cloud

Digital Health

Digital Media and Entertainment

Electronic Gaming

Financial Services

Fintech

FoodTech and AgTech

Global Generics

Internet

Life Sciences

Medical Devices

Mobile Devices

Mobility

Semiconductors

Software

Attorneys

focused on this industry

events

we organize for you

recent news

we want to share with you

other industries

we have covered

FAQs

Client & Industry News

Events

Entrepreneurs Reports

Videos

International

Investment Services

Sign in

Neuron

1623436179-neuron

neuron news detail

all news

about neuron

<html><head></head><body>On November 13, 2023, Divergent Technologies, Inc., the company that has invented, developed, and commercialized the world&apos;s first end-to-end digital industrial manufacturing system, announced that it has completed a Series D equity financing totaling $230 million. The round was led by a $100 million investment from Hexagon AB and included participation from new and existing institutional and family office investors. Wilson Sonsini Goodrich &amp; Rosati advised Divergent on the transaction. Divergent has created the world&apos;s first end-to-end software-hardware production system for industrial digital manufacturing&#x2014;the Divergent Adaptive Production System (DAPS)&#x2014;allowing customers to design, additively manufacture, and automatically assemble complex structures for automotive, aerospace, and defense applications. DAPS transforms the economics and environmental impact of manufacturing complex structures for vehicles of all types by optimizing designs, dematerializing structures, and eliminating upfront capex.
The Wilson Sonsini team that advised Divergent on the transaction includes <a class="rubycontent-page-link rubycontent-page-1362" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::1362">Adam Bloom</a>, <a class="rubycontent-page-link rubycontent-page-1678" title="Tayler D. Tanner" href="https://www.wsgr.com/en/people/tayler-d-tanner.html" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::1678">Tayler Tanner</a>, <a class="rubycontent-page-link rubycontent-page-208430" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::208430">M. Shin</a>, <a class="rubycontent-page-link rubycontent-page-220351" title="Will Andrews" href="https://www.wsgr.com/en/people/will-andrews.html" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::220351">Will Andrews</a>, and <a class="rubycontent-page-link rubycontent-page-49010193" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::49010193">Mackenzie Tobin</a>. For more information, please see Divergent&#x2019;s <a href="https://www.prnewswire.com/news-releases/divergent-technologies-inc-announces-closing-of-upsized-230-million-series-d-capital-raise-301985962.html">press release</a>.</body></html>

Wilson Sonsini Advises Divergent Technologies, Inc. on Upsized $230 Million Series D

Client Highlights

On November 16, 2023, Nature's Toolbox (NTx), a life sciences company building next generation platforms to manufacture RNA and protein, announced the close of a $47.5 million Series B funding round led by RA Capital Management, with strong participation from existing investors Anzu Partners and BlueStone Venture Partners. Wilson Sonsini Goodrich &amp; Rosati advised NTx on the transaction.
The fundraise will enable NTx to continue to advance its biomanufacturing platforms, NTxscribe&reg; and NTxpress&reg;. Acceleration of these technology foundations will enable distribution of manufacturing capabilities globally, ultimately providing solutions to prepare for future pandemic events, personalized medicine therapy, and increased access to critical vaccines and medicines.
The Wilson Sonsini team that advised NTx on the transaction includes:
Corporate <a href="https://www.wsgr.com/en/people/mark-c-solakian.html">Mark Solakian</a> <a href="https://www.wsgr.com/en/people/jake-d-gatof.html">Jake Gatof</a> <a href="https://www.wsgr.com/en/people/kristen-kercher.html">Kristen Kercher</a> <a href="https://www.wsgr.com/en/people/priyanka-w-nawathe.html">Priyanka Nawathe</a> <a href="https://www.wsgr.com/en/people/reilly-m-clark.html">Reilly Clark</a> <a href="https://www.wsgr.com/en/people/tamara-labanowski.html">Tamara Labanowski</a> <a href="https://www.wsgr.com/en/people/erica-wolfe-heinz.html">Erica Wolfe Heinz</a> <a href="https://www.wsgr.com/en/people/rebecca-lilley.html">Rebecca Lilley</a>
Delaware Law <a href="https://www.wsgr.com/en/people/ryan-j-greecher.html#credentials">Ryan Greecher</a> <a href="https://www.wsgr.com/en/people/james-g-griffin-stanco.html">James Griffin-Stanco</a> <a href="https://www.wsgr.com/en/people/allurie-kephart.html">Allurie Kephart</a> <a href="https://www.wsgr.com/en/people/ryan-hart.html">Ryan Hart</a>
Tax <a href="https://www.wsgr.com/en/people/greg-broome.html">Gregory Broome</a> <a href="https://www.wsgr.com/en/people/anjali-krishnan.html">Anjali Krishnan</a>
Employee Benefits and Compensation <a href="https://www.wsgr.com/en/people/matthew-c-norgard.html">Matthew Norgard</a>
For more information, please see NTx's <a href="https://www.businesswire.com/news/home/20231116412007/en/NTx-Raises-47.5M-in-Series-B-Funding-to-Advance-Next-Generation-Biomanufacturing">news release</a>. Additional coverage can be found on <a href="https://endpts.com/exclusive-ntx-locks-in-47-5m-series-b-to-commercialize-protein-mrna-manufacturing-platforms/">EndPoints News</a>, <a href="https://www.fiercepharma.com/manufacturing/ntx-attracts-big-name-investors-475m-round-advance-next-gen-manufacturing-technology">Fierce Pharma</a>, and <a href="https://www.bizjournals.com/albuquerque/inno/stories/fundings/2023/11/16/natures-toolbox-series-b-funding-round-growth.html">New Mexico Inno</a>.

Wilson Sonsini Advises NTx on $47.5 Million Series B

On November 1, 2023, Infinitum, an Austin, TX-based provider of a sustainable air-core motor, announced $185 million in Series E funding led by Just Climate with participation from Galvanize Climate Solutions and NGP. Existing investors including Alliance Resource Partners (NASDAQ: ARLP), Rockwell Automation (NYSE: ROK), Riverstone Holdings, Chevron Technology Ventures, Cottonwood Technology Fund and Ajax Strategies also participated in this round, bringing total funding to-date to $350 million. Wilson Sonsini Goodrich &amp; Rosati provided legal counsel to Infinitum for this transaction.
The company intends to use the funds to increase production to meet customer demand and drive decarbonization in the industrial sector.
The Wilson Sonsini team that advised Infinitum on the transaction included&nbsp;<a href="https://www.wsgr.com/en/people/brian-dillavou.html">Brian Dillavou</a>, <a href="https://www.wsgr.com/en/people/kimball-smith.html">Kimball Smith</a>, and&nbsp;<a href="https://www.wsgr.com/en/people/vickie-wang.html">Vickie Wang</a>.
For more information, please see Infinitum's&nbsp;<a href="https://www.businesswire.com/news/home/20231101739350/en/Infinitum-Secures-185-Million-Series-E-Funding-Led-by-Just-Climate-to-Catalyze-Industrial-Decarbonization-with-High-Efficiency-Sustainable-Motors">news release</a>. Additional coverage can be found on&nbsp;<a href="https://www.reuters.com/sustainability/cop/efficient-motor-maker-infinitum-raises-185-mln-round-led-by-climate-focused-fund-2023-11-01/#:~:text=The%20money%20raised%20will%20be,100%20patents%20and%20pending%20patents.">Reuters</a>.

Wilson Sonsini Advises Infinitum on $185M Series E Funding

On October 31, 2023, Aqtual, a precision medicine company using its novel cell-free DNA platform to develop products for chronic diseases and oncology, announced it has completed a $16 million Series A round of financing co-led by Genoa Ventures, Manta Ray Ventures, and Yu Galaxy. Wilson Sonsini Goodrich &amp; Rosati advised Aqtual on the transaction.
Aqtual's proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in blood. The platform yields efficient and robust real-time analysis of disease and treatment while overcoming the limitations of previous cell-free DNA methodologies.
The Wilson Sonsini team representing Aqtual in the transaction was led by <a href="https://www.wsgr.com/en/people/mark-c-solakian.html">Mark Solakian</a>, <a href="https://www.wsgr.com/en/people/amanda-k-creedon.html">Amanda Creedon</a>, and <a href="https://www.wsgr.com/en/people/erica-wolfe-heinz.html">Erica Wolfe Heinz</a>.
For more information, please see Aqtual&rsquo;s <a href="https://www.prnewswire.com/news-releases/aqtual-raises-16-million-in-series-a-funds-301972198.html">news release</a>.

Wilson Sonsini Advises Aqtual on Series A Funding

On October 30, 2023, MapLight Therapeutics, a clinical-stage biopharmaceutical company working to develop targeted, novel therapeutics to improve the lives of people with brain disorders, announced a $225 million Series C financing co-led by Novo Holdings, 5AM Ventures, Cowen Healthcare Investments, and other investors. Wilson Sonsini Goodrich &amp; Rosati advised Novo Holdings on the financing.
The additional financing will advance ML-007C-MA, a novel M1/M4 muscarinic agonist agent combined with a precision matched peripheral muscarinic antagonist, into Phase 2 trials for schizophrenia and Alzheimer's disease psychosis in 2024 and enable continued progress on the company's other pipeline programs. In connection with the financing, Jim Trenkle, Ph.D., MBA, Partner in the Venture Investments group at Novo Holdings, will join the MapLight Therapeutics Board of Directors.
Novo Holdings is responsible for managing the assets of Novo Nordisk Foundation, which seeks to improve people&rsquo;s health and the sustainability of society and the planet. The firm invests in life sciences companies and is an asset manager.
The Wilson Sonsini team that advised Novo Holdings on the transaction includes:
Corporate <a href="https://www.wsgr.com/en/people/dan-r-koeppen.html">Dan Koeppen</a> <a href="https://www.wsgr.com/en/people/kassandra-k-castillo.html">Kassandra Castillo</a> <a href="https://www.wsgr.com/en/people/bridget-balisy.html">Bridget Balisy</a>
Patents and Innovations <a href="https://www.wsgr.com/en/people/maya-skubatch.html">Maya Skubatch</a> <a href="https://www.wsgr.com/en/people/gregory-w-mitchell.html">Greg Mitchell</a> <a href="https://www.wsgr.com/en/people/feng-tian.html">Feng Tian</a> <a href="https://www.wsgr.com/en/people/trevor-lyons.html">Trevor Lyons</a>
Regulatory and Compliance <a href="https://www.wsgr.com/en/people/stephen-r-heifetz.html">Stephen Heifetz</a> <a href="https://www.wsgr.com/en/people/jonathan-r-davey.html">Jonathan Davey</a>
For more information, please see MapLight Therapeutics' <a href="https://www.prnewswire.com/news-releases/maplight-therapeutics-closes-225-million-series-c-funding-round-to-advance-pipeline-of-central-nervous-system-therapeutics-301970884.html">news release</a>. Additional coverage can be found on <a href="https://www.finsmes.com/2023/10/maplight-therapeutics-closes-225m-series-c-funding.html">FinSMEs</a>.

Wilson Sonsini Advises Novo Holdings on MapLight Therapeutics’ $225 Million Series C

<html><head></head><body>On October 24, 2023, DermBiont, a clinical-stage biotechnology company advancing targeted topical therapeutics for the treatment of dermatological indications, announced a $35.2 million Series B financing. The financing was led by new institutional investor Double Point Ventures, and included continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others. Wilson Sonsini Goodrich &amp; Rosati provided IP and corporate counsel to DermBiont in the transaction. The proceeds from the financing will be used to advance the clinical development of two drugs: SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novel PKC-beta inhibitor for the treatment of melasma and other hyperpigmentation disorders of the skin. They are expected to fund the company through end of its Phase 2 meetings with the U.S. Food and Drug Administration (FDA), which are expected in the second half of 2024 for both programs. Wilson Sonsini has represented DermBiont on IP matters since the company&#x2019;s inception, and the patent team that advised on the Series B included <a class="rubycontent-page-link rubycontent-page-1192" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::1192">Matt Bresnahan</a>, <a class="rubycontent-page-link rubycontent-page-1377" title="Alicia Umpierre" href="https://www.wsgr.com/en/people/alicia-umpierre.html" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::1377">Alicia Umpierre</a>, <a class="rubycontent-page-link rubycontent-page-224362" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::224362">Dalton Case</a>, and <a class="rubycontent-page-link rubycontent-page-224366" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::224366">Tiara Wong</a>. The Wilson Sonsini corporate team that advised on the transaction included <a class="rubycontent-page-link rubycontent-page-1289" title="Jason M. Skolnik" href="https://www.wsgr.com/en/people/jason-m-skolnik.html" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::1289">Jason Skolnik</a>, <a class="rubycontent-page-link rubycontent-page-250505" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::250505">Dani Glazer Signaigo</a>, and <a class="rubycontent-page-link rubycontent-page-249247" title="Leila Purqurian" href="https://www.wsgr.com/en/people/leila-purqurian.html" data-rubyapp-plugin="rubycontentpagepicker" data-rubyapp-reference="content::249247">Leila Purqurian</a>. For more information, please see DermBiont&#x2019;s <a href="https://www.dermbiont.com/in-the-news/2023/10/24/dermbiont-announces-first-close-of-352-million-in-a-series-b-financing-to-advance-first-in-class-targeted-topical-dermatological-therapeutics">news release</a>.</body></html>

Wilson Sonsini Advises DermBiont on $35.2 Million Series B Financing

On October 17, 2023, Nexu, a Mexico-based provider of an automotive financing platform, announced it has raised $20 million in a Series B round led by Valor Capital Group (Valor Capital) with participation from FinTech Collective and Endeavor Catalyst, as well as previous investors Altos Ventures, Wollef, Squareone, Clocktower Ventures, Gilgamesh Ventures, FJ Labs, Ivernet, and Capem. Wilson Sonsini Goodrich &amp; Rosati advised Valor Capital on the transaction.
Nexu is revolutionizing the Mexican automotive industry, making it easier for drivers to access financing and acquire vehicles. The new funding will enable the company to develop its intelligent platform and expand its operations and services.
The Wilson Sonsini team that advised Valor Capital on the transaction includes <a href="https://www.wsgr.com/en/people/matt-l-squires.html">Matt Squires</a>, <a href="https://www.wsgr.com/en/people/vanessa-jacob-heck.html">Vanessa Jacob Heck</a>, <a href="https://www.wsgr.com/en/people/jose-corte-real.html">Jose Corte-Real</a>, <a href="https://www.wsgr.com/en/people/estefano-martinez.html">Estefano Martinez</a>, and <a href="https://www.wsgr.com/en/people/jacob-morales.html">Jacob Morales</a>.
For more information, please see press coverage on <a href="https://www.axios.com/pro/fintech-deals/2023/10/17/nexu-raises-20-million">Axios</a> and <a href="https://www.finsmes.com/2023/10/nexu-raises-20m-in-series-b-funding.html">FinSMEs</a>.

Wilson Sonsini Advises Valor Capital on Series B Investment in Nexu

On October 19, 2023, Tofu, a San Mateo, CA-based generative AI platform for creating hyper-personalized, omnichannel marketing campaigns at scale, announced that it raised $5 million in seed funding. The round was led by Index Ventures with participation from SignalFire, Stage 2 Capital, and Liquid 2 Ventures. Wilson Sonsini Goodrich &amp; Rosati advised Tofu on the transaction.
Tofu provides B2B marketing teams with a unified platform for creating campaigns at scale that converts leads. It leverages a company&rsquo;s brand guideline and segmentation (personas, industries, accounts, keywords) and uses generative AI to create unlimited variations of on-brand content for ads, emails, social, landing pages, blog posts, case studies, sales enablement, and any other content needs. Tofu then analyzes the characteristics of successful campaigns to recommend tactics to increase conversion on each channel. The company intends to use the funds to expand operations and its business reach.
The Wilson Sonsini team that advised Tofu on the transaction included <a href="https://www.wsgr.com/en/people/yokum-taku.html">Yokum Taku</a>,&nbsp;<a href="https://www.wsgr.com/en/people/avi-emanuel.html">Avi Emanuel</a>,&nbsp;and&nbsp;<a href="https://www.wsgr.com/en/people/jing-zhang.html">Jing Zhang</a>.
For more information, please see Tofu's <a href="https://www.businesswire.com/news/home/20231019167641/en/Tofu-raises-5M-seed-round-to-put-B2B-Marketing-on-Autopilot">news release</a>. Additional coverage can be found on <a href="https://techcrunch.com/2023/10/19/tofu/">TechCrunch</a>.

Wilson Sonsini Advises Tofu on $5 Million Seed Financing

ECP Attorneys:

insight detail

all insights

we want to share with you

All videos

all insights.css-1mrua6o{margin-top:8px;margin-bottom:0;}.css-1ic8ug3{box-sizing:border-box;margin:0;min-width:0;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;margin-top:8px;margin-bottom:0;}

.css-vurnku{box-sizing:border-box;margin:0;min-width:0;}we want to sharewith you

all insights

we want to share
with you